Opinion|Videos|March 13, 2026
Remaining Evidence Gaps in EGFR-Mutated NSCLC Care
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss remaining evidence gaps in EGFR-mutated NSCLC care.
Advertisement
Episodes in this series
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, identify persistent evidence gaps in the management of EGFR-mutated non–small cell lung cancer. Vokes highlights unanswered questions regarding optimal combination strategies, duration of therapy, and sequencing after novel frontline regimens. Devarakonda underscores the need for biomarker-driven research and real-world data to refine treatment algorithms.
Advertisement
Related to this article
Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.
Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.
Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.
The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
4
Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer
5